A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
Part of paid clinical trials in Detroit, Michigan.
- Sponsor
- Mirati Therapeutics Inc.
- Study ID
- NCT00975767
- Phase
- PHASE1
- Status
- Terminated
Conditions
- Advanced Malignancies, Non-small Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- MGCD265+erlotinib — DRUGMGCD265 and erlotinib administered daily
- MGCD265+docetaxel — DRUGMGCD265 administered daily; docetaxel administered once every 3 weeks
Study Details
The main purpose of this study is to assess the safety profile of MGCD265 when administered in combination with the marketed anticancer drugs erlotinib and docetaxel.
Key Dates
- First listed
- Sep 11, 2009
- Start date
- Aug 31, 2009
- Status verified
- Jan 2015
- Primary completion
- Jul 31, 2013
- Completion
- Aug 31, 2014
Study Design
- Enrollment
- 126 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: MGCD265+erlotinib
- Experimental: MGCD265+docetaxel
Primary Outcome Measure
Phase I: Safety profile (including maximum tolerated dose and dose limiting toxicities) [ Time Frame: 1 year ]
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Barbara Ann Karmanos Cancer Center | Detroit | Michigan | 48201 | - |
| Duke University Medical Center | Durham | North Carolina | 27710 | - |
| University of Pennsylvania Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | - |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | - |
| South Texas Accelerated Research Therapeutics, LLC | San Antonio | Texas | 78229 | - |
Find similar trials in Detroit, MI
By research site